Cargando…
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Association for the Study of Intestinal Diseases
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077317/ https://www.ncbi.nlm.nih.gov/pubmed/30090051 http://dx.doi.org/10.5217/ir.2018.16.3.499 |
| _version_ | 1783344886847635456 |
|---|---|
| author | Motoya, Satoshi Watanabe, Mamoru Kim, Hyo Jong Kim, Young Ho Han, Dong Soo Yuasa, Hirotoshi Tabira, Junichi Isogawa, Naoki Arai, Shoko Kawaguchi, Isao Hibi, Toshifumi |
| author_facet | Motoya, Satoshi Watanabe, Mamoru Kim, Hyo Jong Kim, Young Ho Han, Dong Soo Yuasa, Hirotoshi Tabira, Junichi Isogawa, Naoki Arai, Shoko Kawaguchi, Isao Hibi, Toshifumi |
| author_sort | Motoya, Satoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6077317 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Korean Association for the Study of Intestinal Diseases |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60773172018-08-08 Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies Motoya, Satoshi Watanabe, Mamoru Kim, Hyo Jong Kim, Young Ho Han, Dong Soo Yuasa, Hirotoshi Tabira, Junichi Isogawa, Naoki Arai, Shoko Kawaguchi, Isao Hibi, Toshifumi Intest Res Corrigenda and Errata Korean Association for the Study of Intestinal Diseases 2018-07 2018-07-27 /pmc/articles/PMC6077317/ /pubmed/30090051 http://dx.doi.org/10.5217/ir.2018.16.3.499 Text en © Copyright 2018. Korean Association for the Study of Intestinal Diseases. http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigenda and Errata Motoya, Satoshi Watanabe, Mamoru Kim, Hyo Jong Kim, Young Ho Han, Dong Soo Yuasa, Hirotoshi Tabira, Junichi Isogawa, Naoki Arai, Shoko Kawaguchi, Isao Hibi, Toshifumi Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title | Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title_full | Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title_fullStr | Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title_full_unstemmed | Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title_short | Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| title_sort | corrigendum: tofacitinib induction and maintenance therapy in east asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies |
| topic | Corrigenda and Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077317/ https://www.ncbi.nlm.nih.gov/pubmed/30090051 http://dx.doi.org/10.5217/ir.2018.16.3.499 |
| work_keys_str_mv | AT motoyasatoshi corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT watanabemamoru corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT kimhyojong corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT kimyoungho corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT handongsoo corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT yuasahirotoshi corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT tabirajunichi corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT isogawanaoki corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT araishoko corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT kawaguchiisao corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies AT hibitoshifumi corrigendumtofacitinibinductionandmaintenancetherapyineastasianpatientswithactiveulcerativecolitissubgroupanalysesfromthreephase3multinationalstudies |